top of page

AMENDMENTS TO COMMUNIQUÉ ON PRICING OF MEDICINAL PRODUCTS FOR HUMAN USE



The Communiqué on Pricing of Medicinal Products for Human Use (“Amending Communiqué”) has been published in the Official Gazette dated 31 December 2022 and entered into force.


Regulations adopted by the Amending Communiqué are as follows:


  • The definition of allergy product has been provided and how the allergy products will be priced has been regulated.


  • It has been regulated that up to 15 % more of the prices of products priced based on cost card can be determined as the price of the sales to the warehouse. While 100 % of the total value stated in the cost card could be determined as the price of the sales to the warehouse as per the previous regulation, 115 % of this price would be determined as the price of the sales to the warehouse as per the new regulation.


  • Regulations regarding traditional herbal medicinal products, medicinal teas, homeopathic medicinal products, medicinal products used in aromatherapy, non-reimbursed manufactured products and pricing of imported non-reimbursed products have been adopted.


You can access the Amending Communiqué by clicking this link.

Comments


bottom of page